Cancer Commons

“The form 990 is given to the governing body before the return is filed. They review and can request changes at this time.”

“The officers, directors and key employees are required to review and sign the written conflict of interest policy annually.”

“The board of directors performs all interviews specific to top key positions which is then forwarded to the full board of directors for review and approval.”

“Made available upon request.”

“Shelley frisbie's compensation stated on part vii, section a, line 1a was also included as a payment to an independent contractor on part vii, part b, line 1.”

“Cancer commons brings together a team of nurse navigator, phd scientists, physicians, and national experts, who combine compassion with deep scientific knowledge to help patients understand their disease and access their best treatment options. Cancer types - cancer commons assists patients with various cancer types, particularly those that are difficult to treat. These include, but are not limited to, brain, pancreatic, ovarian, colorectal, breast, lung, and bladdar cancers. Accomplishments across all cancer types include: further enhancement of the registration process which includes a nurse navigator to assist patients and caregivers collect medical records and identify their specific needs including goals of treatment. Increased the library of treatment options for cancer patients, by cancer type, based on the latest clinical and scientific discoveries. Expanded the virtual tumor boards ("vtb") program to include pancreatic as well as brain patients. Vtb is a network of national experts including oncologists, radiation oncologists, surgeons, and clinical scientists, organized by cancer types. These vtbs review individual cancer patients' cases and provide best-in-class, detailed treatment options reports to share with the patients' oncologists and medical teams. A newly revised brand and website platform launced on july 31, 2021, which helped support the tremendous influx of new patients (74.5% increase in new patients over previous fiscal year). Continued posting and publishing of an educational series of articles to inform patients of the latest advancements in the first of precision technology. Partnership with xcures - patients are invited to enroll in a "perpetual clinical trial" that cancer commons is running in partnership with technology partner xcures. This perpetual trial is open to patients receiving care in the u.s., which allows the organization to learn from each patient to help similar patients, and eventually, all future patients. Xcures currently has 1,168 patients enrolled in the project, of which 716 were added during the year ended june 30, 2021. Other partnerships - cancer commons has partnerships with other organization and institutions who share the cancer commons patient-centric philosophy. These organizations refer patients with challenging cases or offer their services to cancer commons' patients. The most active partners are the pancreatic cancer action network (pancan) and the musella foundation for brain tumor research & information.”

“Consulting fees: program service expenses 229,721. Management and general expenses 20,346. Fundraising expenses 45,638. Total expenses 295,705. Marketing: program service expenses 139,298. Management and general expenses 0. Fundraising expenses 0. Total expenses 139,298.”

“The process has not changed from the prior year.”